OncoHost, a Binyamina, Istrael-based precision oncology firm targeted on advancing improved personalised most cancers remedy, raised $35M in Series C funding.
The spherical was led by Alive Israel HealthTech VC, Leumi Partners, Menora Mivtachim, and OurCrowd. Alive’s co-founder and basic managing accomplice, Prof. Ari Shamiss, was not too long ago named a brand new member of OncoHost’s board.
The firm intends to make use of the funds to broaden its ongoing multicenter PROPHETIC trial, which makes use of PROphet®, its machine learning-based host response profiling platform, and assist the upcoming U.S. business launch of the precision oncology diagnostic answer.
Led by CEO Dr. Ofer Sharon, OncoHost combines life-science analysis and superior machine studying expertise to develop personalised methods for the success of most cancers remedy. Utilizing proprietary proteomic evaluation, the corporate goals to know sufferers’ distinctive response to remedy and overcome one of many main obstacles in medical oncology at the moment – resistance to remedy. Its host response profiling platform, PROphet®, analyzes proteomic modifications in blood samples to watch the dynamics of organic processes induced by the affected person (i.e., the host) in response to a given most cancers remedy.
The firm continues to open further medical trial websites all over the world and might be increasing its analysis to additional most cancers indications. PROphet® is ready to business launch in the U.S. in the third quarter of 2022.